Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jeff Yaremko & Kevin Walby. (2023) Slow Panic? The Regulation of Salvia Divinorum in Canada, 1991-2019. Deviant Behavior 44:8, pages 1179-1193.
Read now
Read now
Articles from other publishers (25)
Abdulselam Ertas, Serkan Yigitkan & Ilkay Erdogan Orhan. (2023) A Focused Review on Cognitive Improvement by the Genus Salvia L. (Sage)—From Ethnopharmacology to Clinical Evidence. Pharmaceuticals 16:2, pages 171.
Crossref
Crossref
Megan I. Chambers, Justine E. Giffen-Lemieux & Rabi A. Musah. (2022)
Rapid Detection and Quantification of Hallucinogenic Salvinorin A in Commercial
Salvia divinorum
Products by DART-HRMS
. ACS Omega 8:1, pages 761-770.
Crossref
Crossref
American Psychiatric Association. 2022. Diagnostic and Statistical Manual of Mental Disorders. Diagnostic and Statistical Manual of Mental Disorders.
Arie P. Francis & Silas W. Smith. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
57
84
.
Andreia Machado Brito-da-Costa, Diana Dias-da-Silva, Nelson G. M. Gomes, Ricardo Jorge Dinis-Oliveira & Áurea Madureira-Carvalho. (2021) Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects. Pharmaceuticals 14:2, pages 116.
Crossref
Crossref
Antoine Karam, Aida Said, Chafika Assaad, Souheil Hallit, Georges Haddad, Dory Hachem & Francois Kazour. (2018) Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence. Community Mental Health Journal 55:4, pages 702-708.
Crossref
Crossref
Joseph El-Khoury & Evelyne Baroud. (2018)
Case series:
Salvia divinorum
as a potential addictive hallucinogen
. The American Journal on Addictions 27:3, pages 163-165.
Crossref
Crossref
A Pourmand, M Mazer-Amirshahi, S Chistov, A Li & M Park. (2017) Designer drugs: Review and implications for emergency management. Human & Experimental Toxicology 37:1, pages 94-101.
Crossref
Crossref
Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott & Jim McCambridge. (2017) The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research 5:4, pages 1-138.
Crossref
Crossref
André Cruz, Sara Domingos, Eugenia Gallardo & Ana Martinho. (2017) A unique natural selective kappa -opioid receptor agonist, salvinorin A, and its roles in human therapeutics. Phytochemistry 137, pages 9-14.
Crossref
Crossref
Matthew W Johnson, Katherine A MacLean, Michael J Caspers, Thomas E Prisinzano & Roland R Griffiths. (2016) Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. Journal of Psychopharmacology 30:4, pages 323-329.
Crossref
Crossref
Rathi Mahendran, Haikel A. Lim, Joyce Y.S. Tan, Shi Min Chua & Munidasa Winslow. (2015)
S
alvia divinorum
: An overview of the usage, misuse, and addiction processes
. Asia-Pacific Psychiatry 8:1, pages 23-31.
Crossref
Crossref
Eduardo R. Butelman & Mary Jeanne Kreek. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
739
746
.
Peter H. Addy. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
733
738
.
Eduardo R. Butelman & Mary Jeanne Kreek. (2015) Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Frontiers in Pharmacology 6.
Crossref
Crossref
Peter H Addy, Albert Garcia-Romeu, Matthew Metzger & Jenny Wade. (2015)
The subjective experience of acute, experimentally-induced
Salvia divinorum
inebriation
. Journal of Psychopharmacology 29:4, pages 426-435.
Crossref
Crossref
Rafael Hernández-Bello, Rosa Virginia García-Rodríguez, Karlina García-Sosa, Luis Manuel Peña-Rodríguez, Maribel Vázquez-Hernández, Fernando Rafael Ramos-Morales, Olivia Corcoran & Alberto Sánchez-Medina. (2015) Salvinorin A content in legal high products of Salvia divinorum sold in Mexico. Forensic Science International 249, pages 197-201.
Crossref
Crossref
O. Hayden GriffinIIIIII. 2014. Prohibition, Religious Freedom, and Human Rights: Regulating Traditional Drug Use. Prohibition, Religious Freedom, and Human Rights: Regulating Traditional Drug Use
149
164
.
Arpana Agrawal & Michael T. Lynskey. 2014. Behavior Genetics of Psychopathology. Behavior Genetics of Psychopathology
185
230
.
Jolanta B. Zawilska & Jakub Wojcieszak. (2013)
Salvia divinorum
: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug
. Human Psychopharmacology: Clinical and Experimental 28:5, pages 403-412.
Crossref
Crossref
Katherine A. MacLean, Matthew W. Johnson, Chad J. Reissig, Thomas E. Prisinzano & Roland R. Griffiths. (2012) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology 226:2, pages 381-392.
Crossref
Crossref
Cheryl L. Currie. (2013) Epidemiology of adolescent Salvia divinorum use in Canada. Drug and Alcohol Dependence 128:1-2, pages 166-170.
Crossref
Crossref
Silas W. Smith & Fiona M. Garlich. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances
55
77
.
John Stogner, David N. Khey, O. Hayden GriffinIIIIII, Bryan Lee Miller & John H. BomanIVIV. (2012) Regulating a novel drug: An evaluation of changes in use of Salvia divinorum in the first year of Florida's ban. International Journal of Drug Policy 23:6, pages 512-521.
Crossref
Crossref
Mohini Ranganathan, Ashley Schnakenberg, Patrick D. Skosnik, Bruce M. Cohen, Brian Pittman, R. Andrew Sewell & Deepak Cyril D'Souza. (2012) Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans. Biological Psychiatry 72:10, pages 871-879.
Crossref
Crossref